ICU Strategies for Managing Severe Hypermagnesemia

Abstract

Severe hypermagnesemia is a rare but potentially life-threatening electrolyte disturbance frequently encountered in critical care settings, particularly among patients with renal impairment or excessive magnesium intake. Effective management requires prompt recognition, understanding of underlying pathophysiology, and evidence-based therapeutic interventions. This review synthesizes current epidemiological data, mechanistic insights, diagnostic criteria, and ICU strategies for managing severe hypermagnesemia. Emphasis is placed on recent advances, clinical guidelines, and practical considerations aimed at optimizing outcomes in critically ill patients.

Introduction

Hypermagnesemia, defined as a serum magnesium concentration exceeding 1.05 mmol/L (2.5 mg/dL), becomes severe at levels above 2.0 mmol/L (4.8 mg/dL). While mild cases are often asymptomatic, severe hypermagnesemia can result in profound neuromuscular, cardiovascular, and respiratory compromise, necessitating urgent intervention in the intensive care unit (ICU). The multifaceted etiology, variable clinical presentation, and complex management challenges underscore the need for a comprehensive, guideline-driven approach tailored to the critically ill population.

Epidemiology / Disease Burden

Severe hypermagnesemia remains relatively uncommon in the general population but is more prevalent in specific ICU cohorts. Recent observational studies indicate an incidence of 1.7% to 9% among hospitalized patients, with higher rates in those with chronic kidney disease (CKD), elderly individuals, and those receiving magnesium-containing medications. The mortality associated with severe hypermagnesemia in ICU settings can approach 20%, highlighting its clinical significance. Notably, the increasing use of magnesium for preeclampsia/eclampsia and bowel preparation in elderly or renally compromised patients contributes to its rising incidence in critical care.

Pathophysiology

Magnesium homeostasis is regulated by intestinal absorption, renal excretion, and bone storage. The kidneys are responsible for 70% of daily magnesium excretion. In renal impairment, diminished glomerular filtration and tubular reabsorption lead to accumulation. Exogenous magnesium overload—often iatrogenic—can surpass the excretory capacity, especially in the setting of acute or chronic kidney dysfunction. Elevated serum magnesium depresses neuromuscular transmission by antagonizing calcium at presynaptic nerve terminals and inhibiting acetylcholine release, while cardiovascular effects are mediated through calcium channel blockade, resulting in hypotension, bradyarrhythmias, and conduction disturbances.

Risk Factors

Established risk factors for severe hypermagnesemia in ICU patients include advanced age, chronic kidney disease, acute kidney injury, excessive intake of magnesium-containing antacids or laxatives, preeclampsia treatment, adrenal insufficiency, tumor lysis syndrome, and hypothyroidism. Polypharmacy, especially with medications affecting renal perfusion (e.g., NSAIDs, ACE inhibitors), further compounds risk. Awareness of these factors is essential for prevention and early detection in high-risk populations.

Clinical Features

Clinical manifestations correlate with serum magnesium concentration. Early symptoms (2.5–4.0 mg/dL) include nausea, flushing, and lethargy. Moderate elevations (4.0–6.0 mg/dL) cause diminished deep tendon reflexes, muscle weakness, and hypotension. Severe hypermagnesemia (>6.0 mg/dL) leads to respiratory depression, complete loss of deep tendon reflexes, paralysis, bradyarrhythmias, complete heart block, and cardiac arrest. The insidious onset may delay diagnosis, mandating high clinical suspicion in vulnerable patients.

Diagnosis

Diagnosis hinges on elevated serum magnesium levels in the context of compatible clinical features and risk factors. Laboratory evaluation should include renal function tests, serum electrolytes (particularly calcium, potassium), and ECG monitoring for arrhythmias or conduction delays. Differential diagnosis includes other causes of neuromuscular depression and cardiovascular instability—such as hyperkalemia, hypocalcemia, and drug toxicity. Serial monitoring is crucial for guiding therapy and assessing response to treatment.

Treatment & Management

Management is primarily supportive and directed at magnesium removal and attenuation of its physiological effects. Initial stabilization includes cessation of all magnesium sources, airway protection, and hemodynamic monitoring. Intravenous calcium gluconate (1–2 g IV over 5–10 minutes) serves as an immediate antidote by counteracting magnesium's neuromuscular and cardiovascular effects. Intravenous fluids and loop diuretics (e.g., furosemide) facilitate renal excretion if kidney function is preserved. In patients with significant renal impairment or life-threatening manifestations, hemodialysis is the definitive therapy, rapidly reducing serum magnesium levels. Continuous renal replacement therapy (CRRT) may be preferred in hemodynamically unstable patients.

Recent Advances / Emerging Therapies

Recent advances focus on optimizing extracorporeal removal techniques, including high-flux hemodialysis membranes and individualized CRRT protocols to enhance magnesium clearance. Point-of-care magnesium assays enable rapid bedside monitoring, improving early detection and titration of therapy. Emerging research explores the use of novel pharmacological agents—such as magnesium chelators or selective renal tubular transport modulators—but these remain investigational. Ongoing studies aim to refine risk stratification tools and predictive models for ICU patients at highest risk of severe hypermagnesemia.

Guideline Recommendations

International and national guidelines recommend prompt cessation of exogenous magnesium, intravenous calcium administration for symptomatic patients, and initiation of renal replacement therapy for severe or refractory cases. The Kidney Disease: Improving Global Outcomes (KDIGO) and the American Society of Nephrology (ASN) emphasize individualized treatment based on severity, comorbidities, and renal function. Routine monitoring of magnesium in high-risk ICU populations and judicious use of magnesium-containing medications are strongly advised as preventive measures.

Conclusion

Severe hypermagnesemia is a critical electrolyte emergency in the ICU, necessitating rapid identification, mechanistic understanding, and guideline-driven therapy. Multidisciplinary management—including cessation of magnesium sources, intravenous calcium, fluid resuscitation, and timely renal replacement therapy—can significantly reduce morbidity and mortality. Awareness of risk factors, vigilant monitoring, and adherence to evidence-based protocols remain the cornerstones of optimal care in critically ill patients.